



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

MAERTENS, et al.

Atty. Ref.: 2551-126

Serial No. 09/899,046

Group: 1648

Filed: July 6, 2001

Examiner: WORTMAN

For: NEW SEQUENCE OF HEPATITIS C VIRUS GENOTYPES
AND THEIR USE AS THERAPEUTIC AND DIAGNOSTIC
AGENTS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

March 3, 2004

RECEIVED

MAR 08 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

- 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

03/04/2004 JBALIMAN 00000117 09899046

01 FC:1806

180.00 0P

822874

The following are submitted in the above-identified application in compliance with
37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:


5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- a) The required Statement made in item 8 below; or
- b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- b) The required Statement is stated in item 8 below.
8. Statement under 37 CFR 1.97(e)
- a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

MAERTENS, et al.
Serial No. 09/899,046

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____


B.J. Sadoff
Reg. No. 36,663

1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE

ATTY. DOCKET NO.

SERIAL NO.

CITATION

2551-126

09/899,046

APPLICANT

MAERTENS, et al.

RECEIVED

FILING DATE

GROUP

(Use several sheets if necessary)

July 6, 2001

1648

MAR 08 2004

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
114		6,548,244 B2	04/15/03	Maertens et al	435	5	07/06/2001
120		5,846,704	12/08/98	Maertens et al	435	5	07/18/1994
150		5,514,539	05/07/96	Bukh et al	435	5	06/29/1993
151		5,882,852	03/16/99	Bukh et al	435	5	09/15/1994
152		5,372,928	12/13/94	Miyamura et al	435	5	02/24/1994

FOREIGN PATENT DOCUMENTS

				TRANSLATION			
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	154	0 463 848 A2	01/02/92	Europe			
	153	2 239 245 A	06/26/91	United Kingdom			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

145	Kato et al, Molecular Cloning of the Human Hepatitis C Virus Genome from Japanese Patients with non-A, non-B Hepatitis, Proc. Nat'l. Acad. Sci., Vol. 87, pp. 9524-9528, December 1990
144	van Doorn, J. Gen Virol, 1995, 76:1871-1876
143	Hotta et al, J. Clin Microbiol, 1994 32:3049-3051
127	Wallace et al, Methods Enzymology, 1987, Vol. 152, pp 432-443
125	Enomoto et al, Biochemical and Biophysical Research Communications, There are Two Major Types of Hepatitis C Virus in Japan, Vol. 170, No. 3, 1990, pp 1021-1025
124	Bukh et al, Proc. Natl. Acad. Sci., Sequence Analysis of the 5' Noncoding Region of Hepatitis C Virus, Vol. 89, pp. 4942-4946, June 1992
91	Innis et al, PCR Protocols: A Guide to Methods & Applications, Academic Press, 1990, pp 3-12
92	George, Current Methods in Sequence Comparison and Analysis; Macromolecular Sequencing & Synthesis, 1998, pp 127-149
93	Chen, The Taiwanese Hepatitis C Virus Genome: Sequence Determination and Mapping the 5' Termini of Viral Genomic and Antigenomic RNA ¹ , Virology, 1992 188, pp 102-113
25	Innis et al, Optimization of PCRs, Academic Press, Inc. 1990, pp 3-12
84	Doorn et al, Analysis of Hepatitis C Virus Genotypes by a Line Probe Assay and Correlation With Antibody Profiles, Journal of Hepatology, 1994; 21: pp 122-129
148	Chan, Proc. Natl. Acad. Sci, October 1979, 76, 5036-40 (abstract only)
149	Majzoub et al, Journal of Biological Chemistry, 1983, Vol. 258:14061-14064

*Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.